First generic competition arrives for Pfizer's megablockbuster anti-smoking drug
Since its FDA approval in 2006 as a treatment to help people stop smoking, and even despite the risk of mental health issues added to the label in 2009, Pfizer has found a way to haul in tens of billions from Chantix in the intervening years.
But that high tide is now receding.
Following the loss of US patent protection in November 2020, those monster sales are expected to decline rapidly, with the first generic from Endo’s Par Pharmaceutical looking to take an early crack.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.